留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

利用综合治疗措施进一步提高肝癌肝移植疗效

汪根树

汪根树. 利用综合治疗措施进一步提高肝癌肝移植疗效[J]. 器官移植, 2021, 12(3): 249-256. doi: 10.3969/j.issn.1674-7445.2021.03.001
引用本文: 汪根树. 利用综合治疗措施进一步提高肝癌肝移植疗效[J]. 器官移植, 2021, 12(3): 249-256. doi: 10.3969/j.issn.1674-7445.2021.03.001
Wang Genshu. Improving efficacy of liver transplantation for hepatocellular carcinoma by comprehensive treatment[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 249-256. doi: 10.3969/j.issn.1674-7445.2021.03.001
Citation: Wang Genshu. Improving efficacy of liver transplantation for hepatocellular carcinoma by comprehensive treatment[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 249-256. doi: 10.3969/j.issn.1674-7445.2021.03.001

利用综合治疗措施进一步提高肝癌肝移植疗效

doi: 10.3969/j.issn.1674-7445.2021.03.001
基金项目: 

国家自然科学基金 81170422

国家自然科学基金 81870447

广东省科技计划项目 2017A020215178

详细信息
    作者简介:

    汪根树,医学博士,主任医师,教授,博士研究生导师。擅长肝移植和腹腔镜肝胆手术,在移植肝脏疾病防治和肝癌多学科防治方面有丰富的经验。现任中山大学附属第三医院肝脏外科(肝脏移植)副主任兼二区主任、医学情报中心主任、期刊中心主任和《器官移植》编辑部副主任。兼任中华医学会外科学分会胆道外科学组委员、中华医学会器官移植学分会异种移植学组委员、中国医师协会器官移植医师分会移植外科技术专业委员会委员、亚洲胰腺与胰岛移植协会会员、中国期刊协会医药卫生期刊分会第三届常务委员和国家自然科学基金项目评审专家。主持国家自然科学基金面上项目、广东省自然科学基金、广东省科技计划项目及广州市科技计划项目,担任“973计划”、“863计划”项目以及十一五、十二五科技重大专项和国家自然科学基金重点项目骨干成员。发表SCI论著20余篇,获教育部科学技术进步奖推广类一等奖1项(第10完成人)和广东省科学技术一等奖2项(分别为第7、第11完成人)

    通讯作者:

    汪根树, Email: wgsh168@163.com

  • 中图分类号: R617, R575

Improving efficacy of liver transplantation for hepatocellular carcinoma by comprehensive treatment

More Information
  • 摘要: 超标准原发性肝癌(肝癌)病人的肝移植机会、符合标准的肝癌病人等待肝移植期间因肝癌进展脱失和肝癌肝移植术后复发是当前肝癌肝移植面临的重要问题。近年来仑伐替尼等系统治疗药物及其联合其它治疗的综合治疗在晚期肝癌治疗中获得了突破性疗效,也为肝癌肝移植的降期治疗、桥接治疗和肿瘤复发防治带来了新的希望。基于系统治疗药物的综合治疗可能是提高肝癌肝移植疗效的突破点,值得深入研究。本文介绍了肝癌肝移植的降期治疗、桥接治疗和肿瘤复发防治进展,旨在为临床治疗提供参考。

     

  • [1] 陈万青, 李贺, 孙可欣, 等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5-13. DOI: 10.3760/cma.j.issn.0253-3766.2018.01.002.

    CHEN WQ, LI H, SUN KX, et al. Report of cancer incidence and mortality in China, 2014[J]. Chin J Oncol, 2018, 40(1): 5-13. DOI: 10.3760/cma.j.issn.0253-3766.2018.01.002.
    [2] PARK JW, CHEN M, COLOMBO M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int, 2015, 35(9): 2155-2166. DOI: 10.1111/liv.12818.
    [3] MAZZAFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. DOI: 10.1056/NEJM199603143341104.
    [4] MAZZAFERRO V, BHOORI S, SPOSITO C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience[J]. Liver Transpl, 2011, 17(Suppl 2): S44-S57. DOI: 10.1002/lt.22365.
    [5] SANTOPAOLO F, LENCI I, MILANA M, et al. Liver transplantation for hepatocellular carcinoma: where do we stand? [J]. World J Gastroenterol, 2019, 25(21): 2591-2602. DOI: 10.3748/wjg.v25.i21.2591.
    [6] XU DW, WAN P, XIA Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: a review[J]. World J Gastroenterol, 2016, 22(12): 3325-3334. DOI: 10.3748/wjg.v22.i12.3325.
    [7] 龚新雷, 秦叔逵. 系统化疗治疗晚期肝细胞癌的现状和研究进展[J]. 中国新药杂志, 2014, 23(17): 2008-2017. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201417011.htm

    GONG XL, QIN SK. Current situation and research progress of systemic chemotherapy in the treatment of advanced hepatocellular carcinoma[J]. Chin J New Drugs, 2014, 23(17): 2008-2017. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201417011.htm
    [8] 刘琳, 郑英慧, 韩力, 等. 含奥沙利铂系统化疗方案治疗晚期原发性肝癌有效性和安全性的前瞻性研究荟萃分析[J]. 临床肿瘤学杂志, 2015, 20(9): 769-779. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201509001.htm

    LIU L, ZHENG YH, HAN L, et al. Efficacy and safety of oxaliplatin-based chemotherapy for advanced primary hepatic carcinoma: a systemic review and Meta analysis of prospective studies[J]. Chin Clin Oncol, 2015, 20(9): 769-779. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201509001.htm
    [9] QIN S, WU Q. Systemic chemotherapy with oxaliplatin is a good option for advanced hepatocellular carcinoma[J]. Hepat Oncol, 2015, 2(3): 203-207. DOI: 10.2217/hep.15.14.
    [10] QIN S, GONG X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China[J]. Hepat Oncol, 2016, 3(1): 71-81. DOI: 10.2217/hep.15.42.
    [11] PARIKH ND, WALJEE AK, SINGAL AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis[J]. Liver Transpl, 2015, 21(9): 1142-1152. DOI: 10.1002/lt.24169.
    [12] AFFONSO BB, GALASTRI FL, DA MOTTA LEAL FILHO JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging[J]. World J Gastroenterol, 2019, 25(37): 5687-5701. DOI: 10.3748/wjg.v25.i37.5687.
    [13] PAVEL MC, FUSTER J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: future directions[J]. World J Gastroenterol, 2018, 24(32): 3626-3636. DOI: 10.3748/wjg.v24.i32.3626.
    [14] CHAPMAN WC, MAJELLA DOYLE MB, STUART JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation[J]. Ann Surg, 2008, 248(4): 617-625. DOI: 10.1097/SLA.0b013e31818a07d4.
    [15] YAO FY, KERLAN RK JR, HIROSE R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis[J]. Hepatology, 2008, 48(3): 819-827. DOI: 10.1002/hep.22412.
    [16] RAVAIOLI M, GRAZI GL, PISCAGLIA F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria[J]. Am J Transplant, 2008, 8(12): 2547-2557. DOI: 10.1111/j.1600-6143.2008.02409.x.
    [17] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.

    Branch of Organ Transplantation of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma(2018 edition) [J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [18] KIM MN, KIM BK, HAN KH, et al. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(3): 335-348. DOI: 10.1586/17474124.2015.959929.
    [19] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943. DOI: 10.1016/j.jhep.2011.12.001.
    [20] ROBERTS JP, VENOOK A, KERLAN R, et al. Hepatocellular carcinoma: ablate and wait versus rapid transplantation[J]. Liver Transpl, 2010, 16(8): 925-929. DOI: 10.1002/lt.22103.
    [21] MILLONIG G, GRAZIADEI IW, FREUND MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma[J]. Liver Transpl, 2007, 13(2): 272-279. DOI: 10.1002/lt.21033.
    [22] VICTOR DW 3RD, MONSOUR HP JR, BOKTOUR M, et al. Outcomes of liver transplantation for hepatocellular carcinoma beyond the University of California San Francisco criteria: a single-center experience[J]. Transplantation, 2020, 104(1): 113-121. DOI: 10.1097/TP.0000000000002835.
    [23] CLAVIEN PA, LESURTEL M, BOSSUYT PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol, 2012, 13(1): e11-e22. DOI: 10.1016/S1470-2045(11)70175-9.
    [24] VOLK ML, VIJAN S, MARRERO JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria[J]. Am J Transplant, 2008, 8(4): 839-846. DOI: 10.1111/j.1600-6143.2007.02138.x.
    [25] SHARR WW, CHAN SC, LO CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation[J]. Transplantation, 2014, 97 (Suppl 8): S10-S17. DOI: 10.1097/01.tp.0000446267.19148.21.
    [26] HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
    [27] ZHU XD, TANG ZY, SUN HC. Targeting angiogenesis for liver cancer: past, present, and future[J]. Genes Dis, 2020, 7(3): 328-335. DOI: 10.1016/j.gendis.2020.03.010.
    [28] EILARD MS, ANDERSSON M, NAREDI P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1): 568. DOI: 10.1186/s12885-019-5760-8.
    [29] LIU Z, FU Z, LI G, et al. Downstaging of recurrent advanced hepatocellular carcinoma after lenvatinib treatment: opportunities or pitfalls? a case report[J]. Onco Targets Ther, 2020, 13: 10267-10273. DOI: 10.2147/OTT.S261521.
    [30] DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05.
    [31] NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? [J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617.
    [32] SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4): 1488-1490. DOI: 10.1002/hep.31234.
    [33] TABRIZIAN P, FLORMAN SS, SCHWARTZ ME. PD-1 inhibitor as bridge therapy to liver transplantation? [J]. Am J Transplant, 2020, 21(5): 1979-1980. DOI: 10.1111/ajt.16448.
    [34] LLOVET JM, MAS X, APONTE JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J]. Gut, 2002, 50(1): 123-128. DOI: 10.1136/gut.50.1.123.
    [35] MAJNO P, LENCIONI R, MORNEX F, et al. Is the treatment of hepatocellular carcinoma on the waiting list necessary? [J]. Liver Transpl, 2011, 17 (Suppl 2): S98-S108. DOI: 10.1002/lt.22391.
    [36] CESCON M, CUCCHETTI A, RAVAIOLI M, et al. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. impact on transplantability and recurrence rate[J]. J Hepatol, 2013, 58(3): 609-618. DOI: 10.1016/j.jhep.2012.09.021.
    [37] DÍAZ-SÁNCHEZ A, MATILLA A, NÚÑEZ O, et al. Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival[J]. Gastroenterol Hepatol, 2010, 33(3): 155-164. DOI: 10.1016/j.gastrohep.2009.10.001.
    [38] BHOORI S, SPOSITO C, GERMINI A, et al. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis[J]. Transpl Int, 2010, 23(7): 712-722. DOI: 10.1111/j.1432-2277.2010.01111.x.
    [39] AU KP, CHOK KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: a proposed management algorithm[J]. World J Gastroenterol, 2018, 24(45): 5081-5094. DOI: 10.3748/wjg.v24.i45.5081.
    [40] 刘召波, 栗光明. 肝移植术后肝癌复发防治进展[J]. 临床肝胆病杂志, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.

    LIU SB, LI GM. Advances in the prevention and treatment of hepatocellular carcinoma recurrence after liver transplantation[J]. J Clin Hepatol, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.
    [41] 李海波, 汪国营, 蔡建业, 等. 2020年ATC肝移植研究前沿盘点[J]. 器官移植, 2021, 12(1): 29-36. DOI: 10.3969/j.issn.1674-7445.2021.01.005.

    LI HB, WANG GY, CAI JY, et al. Summary of the research frontiers of liver transplantation in 2020 ATC[J]. Organ Transplant, 2021, 12(1): 29-36. DOI: 10.3969/j.issn.1674-7445.2021.01.005.
    [42] SCHMITZ S, LURJE G, ULMER F, et al. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(3): 228-236. DOI: 10.1016/j.hbpd.2019.01.004.
    [43] HABIBOLLAHI P, HUNT S, GADE T, et al. The impact of bridging LRT on survival in patients listed for liver transplantation[J]. Cardiovasc Intervent Radiol, 2018, 41(1): 112-119. DOI: 10.1007/s00270-017-1759-1.
    [44] 中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
    [45] SARICI B, ISIK B, YILMAZ S. Management of recurrent HCC after liver transplantation[J]. J Gastrointest Cancer, 2020, 51(4): 1197-1199. DOI: 10.1007/s12029-020-00498-6.
    [46] FISHER J, ZEITOUNI N, FAN W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J]. J Am Acad Dermatol, 2020, 82(6): 1490-1500. DOI: 10.1016/j.jaad.2019.07.005.
    [47] ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1.
    [48] DE BRUYN P, VAN GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? [J]. Curr Opin Oncol, 2019, 31(2): 54-64. DOI: 10.1097/CCO.0000000000000505.
    [49] MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631.
    [50] RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet? [J]. Hepatology, 2018, 67(3): 1166-1168. DOI: 10.1002/hep.29575.
    [51] WANG YC, WU TJ, WU TH, et al. The risk factors to predict acute rejection in liver transplantation[J]. Transplant Proc, 2012, 44(2): 526-528. DOI: 10.1016/j.transproceed.2012.01.041.
  • 加载中
图(1)
计量
  • 文章访问数:  246
  • HTML全文浏览量:  102
  • PDF下载量:  21
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-03-22
  • 网络出版日期:  2021-05-19
  • 刊出日期:  2021-05-15

目录

    /

    返回文章
    返回